Anti-TnMUC1 CAR T-Cells With RDE Payload Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR T-cell therapies for cancer treatment face challenges such as cytokine release syndrome, tumor lysis syndrome, B-cell aplasia, and off-target toxicities, while existing regulatory strategies like kill switches and transient CAR expression compromise the long-term surveillance benefit of CAR technology.
Innovation Solution
Development of anti-TnMUC1 chimeric antigen receptors (CARs) with RNA Destabilizing Elements (RDEs) to control payload expression in immune cells, allowing targeted delivery of various therapeutic agents to cancer cells, including cytokines, antibodies, and enzymes, while minimizing off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If kill switch technology is used to control CAR T-cells, then safety against toxicity is improved, but long-term surveillance capability is lost
Solution Approach 1:
The patent implements a dynamic control system where CAR expression can be precisely adjusted over time rather than permanently fixed or completely eliminated. The inducible promoter allows the system to transition between different expression states based on therapeutic needs, enabling both toxicity control and sustained surveillance capability.
Solution Approach 2:
The patent changes the expression parameter of CAR by using an inducible promoter that responds to specific molecular triggers. This allows the CAR expression level to be modulated between high (for tumor killing), low (for surveillance), and off (for toxicity control) states, resolving the contradiction between safety and long-term functionality.
2Object-affected harmful factors
If transient CAR expression is used, then acute toxicity is reduced, but surveillance benefit is sacrificed and acute toxicity control remains difficult
Solution Approach 1:
The patent creates a dynamic CAR expression system that can be adjusted at different time points. Unlike transient expression that permanently loses CAR capability, this system can maintain low-level CAR expression for surveillance while allowing temporary high-expression phases for tumor elimination, then returning to surveillance mode.
Solution Approach 2:
The patent ensures continuous surveillance capability by maintaining the ability to express CAR at low levels indefinitely. The inducible promoter system allows the CAR to remain available for surveillance purposes even when not actively killing tumors, unlike transient expression where the capability is permanently lost after the transient period.
3Duration of action of stationary object
If stable transgenes are inserted into patient T-cells, then long-term surveillance is achieved, but selection pressures lead to non-responsive clones that continue to cause toxicity
Solution Approach 1:
The patent incorporates a feedback control mechanism where CAR expression is continuously regulated by the inducible promoter in response to external molecular signals. This feedback system ensures that all CAR T-cell clones respond uniformly to control signals, preventing the emergence of non-responsive clones that could cause uncontrolled toxicity while maintaining long-term surveillance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RDE-controlled anti-TnMUC1 CARs effectively target cancer cells with precise temporal regulation of payloads, reducing toxicity and enhancing therapeutic efficacy by maintaining long-term surveillance without compromising safety.
Implementation Method 1
The payload expression is controlled by an RNA destabilizing element (RDE)
Data Source
AI summary
Methods and compositions for delivering a payload at TnMUC1 positive cancer cells. Anti-TnMUC1 CARs and transgene payloads can be engineered into immune cells so that the transgene payload is expressed and delivered at desired times from the immune cell. Such anti-TnMUC1 CAR T-cells with transgene payloads can be combined with the administration of other molecules, e.g., other therapeutics such as anticancer therapies.